BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 8420607)

  • 1. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer.
    Hsing AW; Comstock GW
    Cancer Epidemiol Biomarkers Prev; 1993; 2(1):27-32. PubMed ID: 8420607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of radical prostatectomy on serum hormone levels.
    Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
    J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and late long-term effects of vasectomy on serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone levels.
    Mo ZN; Huang X; Zhang SC; Yang JR
    J Urol; 1995 Dec; 154(6):2065-9. PubMed ID: 7500459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial.
    Chen C; Weiss NS; Stanczyk FZ; Lewis SK; DiTommaso D; Etzioni R; Barnett MJ; Goodman GE
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1410-6. PubMed ID: 14693730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of follicle stimulating hormone, luteinizing hormone, prolactin, testosterone, 5 alpha-dihydrotestosterone, 5 alpha-androstane-3 alpha, 17 beta-diol, 5 alpha-androstane-3 beta, 17 beta-diol, and 17 beta-estradiol from male beagles with spontaneous or induced benign prostatic hyperplasia.
    Cochran RC; Ewing LL; Niswender GD
    Invest Urol; 1981 Nov; 19(3):142-7. PubMed ID: 6170603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediagnostic serum hormones and the risk of prostate cancer.
    Nomura A; Heilbrun LK; Stemmermann GN; Judd HL
    Cancer Res; 1988 Jun; 48(12):3515-7. PubMed ID: 3370644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy.
    Heracek J; Urban M; Sachova J; Kuncova J; Eis V; Mandys V; Hampl R; Starka L
    Neuro Endocrinol Lett; 2007 Feb; 28(1):45-51. PubMed ID: 17277727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of prostate growth.
    Coffey DS; Isaacs JT
    Urology; 1981 Mar; 17(Suppl 3):17-24. PubMed ID: 6163242
    [No Abstract]   [Full Text] [Related]  

  • 10. High-grade prostate cancer is associated with low serum testosterone levels.
    Schatzl G; Madersbacher S; Thurridl T; Waldmüller J; Kramer G; Haitel A; Marberger M
    Prostate; 2001 Apr; 47(1):52-8. PubMed ID: 11304729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum androgens: associations with prostate cancer risk and hair patterning.
    Demark-Wahnefried W; Lesko SM; Conaway MR; Robertson CN; Clark RV; Lobaugh B; Mathias BJ; Strigo TS; Paulson DF
    J Androl; 1997; 18(5):495-500. PubMed ID: 9349747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum levels of gonadotrophins, testosterone and estradiol in acne vulgaris].
    Krause W
    Hautarzt; 1977 Jul; 28(7):368-70. PubMed ID: 142752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormones and the pathophysiology of fibrocystic mastopathy: elevated luteinizing hormone levels.
    Golinger RC; Krebs J; Fisher ER; Danowski TS
    Surgery; 1978 Aug; 84(2):212-5. PubMed ID: 684613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk.
    Dorgan JF; Longcope C; Stephenson HE; Falk RT; Miller R; Franz C; Kahle L; Campbell WS; Tangrea JA; Schatzkin A
    Cancer Epidemiol Biomarkers Prev; 1996 Jul; 5(7):533-9. PubMed ID: 8827358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
    Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
    Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma endothelin and LH-RH, LH, FSH, prolactin, progesterone, 17alpha-hydroxyprogesterone, estrone, 17beta-estradiol, delta4-androstenedione, testosterone, active renin, angiotensin-II and ANP levels in blood and LH, estrone and 17beta-estradiol and pregnanediol levels in urine of normal cycling women.
    Usuki S; Kondoh K; Kubo T
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S421-7. PubMed ID: 11078439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study.
    de Jong FH; Oishi K; Hayes RB; Bogdanowicz JF; Raatgever JW; van der Maas PJ; Yoshida O; Schroeder FH
    Cancer Res; 1991 Jul; 51(13):3445-50. PubMed ID: 1711411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hormone determinations in andrology].
    Frick J
    Andrologia; 1980; 12(3):211-8. PubMed ID: 6778255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of hypothalamic-pituitary-testicular axis hormones in men with or without prostate cancer or atypical small acinar proliferation.
    Schmitt Cda S; Rhoden EL; Almeida GL
    Clinics (Sao Paulo); 2011; 66(2):183-7. PubMed ID: 21484031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigative clinical study on prostate cancer part VII: prolactin and the pituitary-testis-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
    Porcaro AB; Ghimenton C; Petrozziello A; Migliorini F; Romano M; Sava T; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C; Comunale L
    Anticancer Res; 2011 Nov; 31(11):3913-20. PubMed ID: 22110219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.